Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Compugen Ltd. CGEN
$0.76
+$0.01 (1.92%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
65115712.00000000
-
week52high
2.36
-
week52low
0.51
-
Revenue
7500000
-
P/E TTM
-2
-
Beta
2.70899600
-
EPS
-0.42000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 23 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 08 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 08 авг 2022 г. |
| Jefferies | Hold | Buy | 05 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 25 февр 2022 г. |
| Oppenheimer | Outperform | Outperform | 15 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023
PRNewsWire
01 мая 2023 г. в 07:00
HOLON, Israel , May 1, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023, before the U.S. financial markets open.
Why Compugen Shares Are Up Today
The Motley Fool
28 февр 2023 г. в 12:17
The company released its fourth-quarter and full-year results after the bell Monday.
Compugen Ltd. (CGEN) Q4 2022 Earnings Call Transcript
Seeking Alpha
27 февр 2023 г. в 13:10
Compugen Ltd. (NASDAQ:CGEN ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - Chief Medical Officer Eran Ophir - SVP, Research and Drug Discovery Alberto Sessa - CFO Conference Call Participants Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Asthika Goonewardene - Truist Securities Daina Graybosch - SVB Securities Charles Butler - EF Hutton Operator Ladies and gentlemen, thank you for joining us today.
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023
PRNewsWire
13 февр 2023 г. в 07:00
HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023, before the U.S. financial markets open.
Why Compugen Stock Got Slammed Today
The Motley Fool
08 февр 2023 г. в 17:25
Clinical-stage biotechs are particularly susceptible to shifts in analyst sentiment.